Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

NCT06800313 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT06800313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06800313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 6, 2025
Completion date
August 17, 2028
Enrollment
190 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer